Evan R Delgado
Overview
Explore the profile of Evan R Delgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehrich B, Monga S, Delgado E, Lehrich B, Yasaka T, Delgado E, et al.
Res Sq
. 2024 Dec;
PMID: 39711542
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in (encoding for β-catenin), , or ,...
2.
Lehrich B, Tao J, Liu S, Hirsch T, Yasaka T, Cao C, et al.
JHEP Rep
. 2024 Nov;
6(12):101186.
PMID: 39583094
Background & Aims: Patients with β-catenin (encoded by )-mutated hepatocellular carcinoma (HCC) demonstrate heterogenous responses to first-line immune checkpoint inhibitors (ICIs). Precision-medicine based treatments for this subclass are currently in...
3.
Hu Z, Kurihara T, Sun Y, Cetin Z, Florentino R, Faccioli L, et al.
bioRxiv
. 2024 May;
PMID: 38712079
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, and commonly associated with hepatic fibrosis or cirrhosis. This study aims to establish a rat model mimicking the progression from...
4.
Lehrich B, Delgado E
Organogenesis
. 2024 Feb;
20(1):2313696.
PMID: 38357804
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality globally. HCC is highly heterogenous with diverse etiologies leading to different driver mutations potentiating unique tumor immune microenvironments....
5.
Roy N, Alencastro F, Roseman B, Wilson S, Delgado E, May M, et al.
Am J Pathol
. 2022 Jun;
192(9):1259-1281.
PMID: 35718058
Nonalcoholic fatty liver disease (NAFLD) is an epidemic affecting 30% of the US population. It is characterized by insulin resistance, and by defective lipid metabolism and mitochondrial dysfunction in the...
6.
Ma J, Tan X, Kwon Y, Delgado E, Zarnegar A, DeFrances M, et al.
Cell Mol Gastroenterol Hepatol
. 2021 Nov;
13(2):565-582.
PMID: 34756982
Background & Aims: Nonalcoholic fatty liver disease is a frequent cause of hepatic dysfunction and is now a global epidemic. This ailment can progress to an advanced form called nonalcoholic...
7.
Delgado E, Erickson H, Tao J, Monga S, Duncan A, Anakk S
Mol Cell Biol
. 2021 Feb;
41(4).
PMID: 33526450
IQ motif-containing GTPase-activating protein 1 (IQGAP1) is a ubiquitously expressed scaffolding protein that is overexpressed in a number of cancers, including liver cancer, and is associated with protumorigenic processes, such...
8.
Takeishi K, Collin de lHortet A, Wang Y, Handa K, Guzman-Lepe J, Matsubara K, et al.
Cell Rep
. 2020 Jun;
31(9):107711.
PMID: 32492423
The availability of an autologous transplantable auxiliary liver would dramatically affect the treatment of liver disease. Assembly and function in vivo of a bioengineered human liver derived from induced pluripotent...
9.
Stahl E, Delgado E, Alencastro F, LoPresti S, Wilkinson P, Roy N, et al.
Am J Pathol
. 2019 Dec;
190(2):372-387.
PMID: 31843499
Aging is associated with inflammation and metabolic syndrome, which manifests in the liver as nonalcoholic fatty liver disease (NAFLD). NAFLD can range in severity from steatosis to fibrotic steatohepatitis and...
10.
Wilkinson P, Alencastro F, Delgado E, Leek M, Weirich M, Otero P, et al.
Am J Pathol
. 2019 Apr;
189(6):1241-1255.
PMID: 30928253
The liver contains diploid and polyploid hepatocytes (tetraploid, octaploid, etc.), with polyploids comprising ≥90% of the hepatocyte population in adult mice. Polyploid hepatocytes form multipolar spindles in mitosis, which lead...